Home Bratislava Medical Journal 2015 Bratislava Medical Journal Vol.116, No.10, p.580–581, 2015

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.2

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.116, No.10, p.580–581, 2015

Title: Novel potential for the management of Alzheimer disease
Author: E. Ginter, V. Simko, D. Weinrebova, Z. Ladecka

Abstract: Pathologic characteristics of Alzheimer disease (AD) are β-amyloid (Aβ) plaques, neurofibrillary tangles (NFT) and neurodegeneration. Currently, there is no cure for AD. Cilostazol, a selective inhibitor of type 3 phosphodiesterase, is likely to be a promising agent for AD. In the brain of the experimental animals it significantly reduced the Aβ amyloid plaques. Initial clinical reports on the effect of Cilostazol in AD patients are promising. In mice, stem cells favourably influence the pathogenetic process critical in AD, by reducing deposits of Aβ plaques. Clinical trials of the drug, called Betablock, are already underway in Britain. Successful management and resolution of AD in man will still require further intensive research (Fig. 4, Ref. 11).

Keywords: Alzheimer disease, β-amyloid plaques, Cilostazol, stem cells.
Published online: 28-Oct-2015
Year: 2015, Volume: 116, Issue: 10 Page From: 580, Page To: 581
doi:10.4149/BLL_2015_112


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.